Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Point Therapeutics (MM) Charts. Click Here for more Point Therapeutics (MM) Charts.](/p.php?pid=staticchart&s=N%5EPOTP&p=8&t=15)
Point Therapeutics, Inc. (NASDAQ:POTP) announced today
that it will host a live webcast on Tuesday, January 31 at 7:30 AM
EST. "As the new year begins, we would like to provide our new
investors and long-term shareholders a clinical update regarding the
design and strategy behind our Phase 3 metastatic non-small cell lung
cancer program and our on-going Phase 2 studies," said Don Kiepert,
Chairman and Chief Executive Officer.
The webcast may be accessed by visiting www.pther.com
About Point Therapeutics, Inc.:
Point is developing a family of dipeptidyl peptidase (DPP)
inhibitors for use in cancer, type 2 diabetes and as vaccine
adjuvants. The Company is currently studying its lead product
candidate, talabostat, in a Phase 3 program in metastatic NSCLC.
Additionally, talabostat is being evaluated in several Phase 2 trials;
including, as a single-agent in metastatic melanoma, in combination
with cisplatin in metastatic melanoma, in combination with rituximab
in advanced chronic lymphocytic leukemia, and in combination with
gemcitabine in metastatic pancreatic cancer. Point's portfolio also
includes two other DPP inhibitors in preclinical development--PT-630
for type 2 diabetes, and PT-510 as a vaccine adjuvant.
Certain statements contained herein are not strictly historical
and are "forward looking" statements as defined in the Private
Securities Litigation Reform Act of 1995. This information includes
statements with respect to the company's clinical development programs
and the timing of initiation and completion of its clinical trials.
Forward-looking statements are statements that are not historical
facts, and can be identified by, among other things, the use of
forward-looking language, such as "believes," "feels," "expects,"
"may," "will," "should," "seeks," "plans," "schedule to,"
"anticipates" or "intends" or the negative of those terms, or other
variations of those terms of comparable language, or by discussions of
strategy or intentions. A number of important factors could cause
actual results to differ materially from those projected or suggested
in the forward looking statement, including the risk factors described
in Point's quarterly report on Form 10-Q for the quarter ended
September 30, 2005 and from time to time in Point's periodic and other
reports filed with the Securities and Exchange Commission.